How did Supriya Lifescience perform in the final quarter of FY26?

The company reported revenue of **₹276.5 crore**, a **50%** increase over the same period last year. Net profit for the quarter rose **47%** to **₹74.2 crore**.

What dividend did the board recommend?

The board recommended a final dividend of **₹1** per equity share.

How does the Q4 performance compare to the rest of the year?

The growth in the final quarter shows a significant acceleration compared to the overall annual growth rate, indicating a strong finish to the fiscal year.

Earnings · CDMO · Mid cap

Supriya Lifescience ends FY26 with a 50% revenue jump in Q4

Q: What were the full-year results for FY26?

Supriya Lifescience recorded a total income of **₹839.4 crore** and a net profit of **₹209.1 crore** for the full fiscal year.

The pharmaceutical firm posted a strong finish to the fiscal year, with quarterly profit rising 47% to ₹74.2 crore and a dividend of ₹1 per share.

— 1 earlier story on Supriya Lifescience Ltd. →

SUPRIYA 27 May 2026 · 6:50 PM IST Verify on BSE · NSE

Mkt cap₹6,497 cr

P/E35.07×

ROE18.86%

Debt / eq.0.00

Div yld0.13%

₹276.5 cr Q4 revenue, marking a 50% year-on-year increase.

What's new

Q4 revenue climbed 50% year-on-year to ₹276.5 crore.
Net profit for the quarter reached ₹74.2 crore, up 47%.
The board recommended a final dividend of ₹1 per equity share.

Why this matters

The final quarter growth significantly outpaced the company's full-year performance. This acceleration suggests a strong operational finish to the fiscal year.

What we're watching

Whether this growth momentum carries into the first quarter of FY27.
Management commentary on the sustainability of these margins.
The ex-dividend date for the ₹1 per share payout.

The full read

Supriya Lifescience finished FY26 with a surge in activity. The company reported Q4 revenue of ₹276.5 crore, a 50% increase compared to the same period last year. Net profit for the quarter rose 47% to ₹74.2 crore.

Growth accelerated.

For the full fiscal year, the company posted a total income of ₹839.4 crore and a net profit of ₹209.1 crore, while the board recommended a final dividend of ₹1 per share to reward shareholders for this strong operational finish to the fiscal year.

Questions answered

How did Supriya Lifescience perform in the final quarter of FY26?: The company reported revenue of ₹276.5 crore, a 50% increase over the same period last year. Net profit for the quarter rose 47% to ₹74.2 crore.
What were the full-year results for FY26?: Supriya Lifescience recorded a total income of ₹839.4 crore and a net profit of ₹209.1 crore for the full fiscal year.
What dividend did the board recommend?: The board recommended a final dividend of ₹1 per equity share.
How does the Q4 performance compare to the rest of the year?: The growth in the final quarter shows a significant acceleration compared to the overall annual growth rate, indicating a strong finish to the fiscal year.

Mentioned: Supriya Lifescience · FY26

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on SUPRIYA →

27 May 2026 · 6:50 PM IST Supriya Lifescience ends FY26 with a 50% revenue jump in Q4
today Supriya Lifescience profit jumps 47% in Q4